Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.
Companies in the News
Biotech
Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders
Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.
Anatara Lifesciences Ltd (ASX:ANR) Receives R&D Tax Refund
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.
Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'
Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).
Anatara Lifesciences Ltd (ASX:ANR) APVMA Submission Major Milestone Achieved
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.
Lachesis Biosciences Limited ASX Initial Public Offer - Prospectus and Application
Lachesis Biosciences Limited are pleased to provide a Prospectus to raise up to $6,000,000 by an Offer to the public comprising: Offer of 5,000,000 New Shares at an issue price of $1.00 each totaling $5,000,000; and Oversubscriptions of up to a maximum of $1,000,000.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- VIDEO: Lion Selection Group Ltd (ASX:LSX) CEO Hedley Widdup and Sean Russo Talk at the Australian Gold Conference 2024
- VIDEO: The Australian Gold Conference 2024 - Education Evening with Expert Panel
- Lithium Universe Ltd (ASX:LU7) Finalises Frankfurt and US OTC Listing
Social Media
